Communities and Civil Society at the Sixth Preparatory Meeting welcome the Investment Case released by the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) for its Sixth Replenishment during the Preparatory Meeting held in New Delhi on the 7 & 8 February 2019 with the auspices of the Government of India. We acknowledge the rationale provided in the Investment Case which calls for at least US$14 billion based on the Global Plans for the three diseases. We emphasise that the US$14 billion investment is the bare minimum required to achieve the Global Fund Strategy goals for 2017 – 2022. We are concerned that the majority of the increase of investments for the three diseases from US$66 billion in the current cycle to US$83 billion for the next three-year cycle is expected from increased domestic financing. We are alarmed that the total investment including the minimum US$14 billion investment in Global Fund, increased domestic financing and sustained external funding represents only 82% of the required resources leaving a US$18 billion gap to reach the targets set out in the Global Plans.



Read More

Zimbabwe is one of the seven African countries where clinical trials for a long-lasting injectable antiretroviral drug developed in Uganda will be conducted.

Uganda Virus Research Institute Uganda, which has already started recruiting women for trials for the injectable drug for Pre-Exposure Prophylaxis, is taking the lead with Zimbabwe joining Kenya, Malawi, Botswana, Zimbabwe, South Africa and Swaziland for the large scale trials.

A total of 3 200 individuals are expected to be recruited into the study across the seven countries. It will run over a five-year period.

With an adult prevalence rate of 13,7 percent, Zimbabwe is one of the five countries hardest hit by the HIV and Aids pandemic globally.

HIV/Aids drug trials for Zimbabwe

Low absorption of funds within Global Fund grants has been a persistent and pervasive challenge in grant implementation, especially in sub-Saharan Africa, which receives about two third of Global Fund investment. This question was again debated in the African Constituencies (Eastern and Southern Africa and West and Central Africa) annual consultative meeting of the Global Fund that was held from 18-19 October 2018, in Addis Ababa, Ethiopia.

Participants of the meeting came from the 46 countries within the constituencies, and also present were six participants from the Global Fund Secretariat, three from UNAIDS, and Global Fund Board Chair Aida Kurtovic. Representing the countries were the two board representatives for each constituency, their respective alternates from the African Constituency, representatives of the Country Coordinating Mechanism (CCM), and State Principal Recipients.

An innovative development fund that champions women and children has raised over US $1 billion to support health systems across the world.

At a conference in Oslo, co-hosted by the governments of Norway and Burkina Faso, 14 donors pledged hundreds of millions of dollars to enable the Global Financing Facility (GFF) to improve the lives of women in dozens of low and middle income countries.

26 October 2018 │The Hague, The Netherlands - The 2018 Kochon Prize was awarded on Tuesday, 23 October to Minister of Health of South Africa Dr Aaron Motsoaledi and to the Global TB Caucus for outstanding political leadership to end TB. Mr Mualidi Ntahondi Nyamlenganwa, of the volunteer group MKUTA, based in Tanzania, received an honorary award from the Stop TB Partnership for Community Leadership and Mobilization.


World Mental Health Day is observed on 10 October each year. This year, UNAIDS is highlighting that governments need to do more to integrate mental health and HIV services.

People living with HIV are at a greatly increased risk of developing mental health conditions, often suffering from depression and anxiety as they adjust to their diagnosis and adapt to living with a chronic infectious disease.